No black box warning on record for Gemcitabine

As of the latest FDA labeling reviewed, Gemcitabine (GEMCITABINE HYDROCHLORIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Gemcitabine medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Schedule-Dependent Toxicity: Increased toxicity with infusion time greater than 60 minutes or dosing more frequently than once weekly. ( 5.1 ) • Myelosuppression: Monitor for myelosuppression prior to each cycle and reduce or withhold dose for severe myelosuppression. ( 5.2 ) • Severe Cutaneous Adverse Reactions (SCARs): Permanently discontinue Gemcitabine Injection if

No black box warning on record for Gemcitabine

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Schedule-Dependent Toxicity: Increased toxicity with infusion time greater than 60 minutes or dosing more frequently than once weekly. ( 5.1 ) • Myelosuppression: Monitor for myelosuppression prior to each cycle and reduce or withhold dose for severe myelosuppression. ( 5.2 ) • Severe Cutaneous Adverse Reactions (SCARs): Permanently discontinue Gemcitabine Injection if

Gemcitabine Black Box Warning

No black box warning on record for Gemcitabine

Other warnings & precautions

Gemcitabine Black Box Warning

No black box warning on record for Gemcitabine

Other warnings & precautions